About Company

• Entero Healthcare Solutions Limited (“Entero”) was incorporated on January 10, 2018. Entero is a wholesale distribution healthcare platform which caters to retail pharmacies, hospitals, nursing homes, clinics, and physicians.

• In addition, it also offers marketing and promotion services, patient support & access services to pharmaceutical and medical device companies. Furthermore, it provides technology solutions to retailers and distributors across the pharma value chain to help order management, inventory management etc.

• Entero has nationwide presence of 77 distribution warehouses located across 38 cities in 19 states and union territories, and a customer base of over 73,700 pharmacies and 2,800 hospitals spread across 501 districts, as of September 30, 2023

• Entero is among the top-3 healthcare products distributor in India in terms of revenue in fiscal 2022. The company reported operating income of ?3,300.21 crore in fiscal 2023.

• Entero has achieved fastest scale up of operations among the healthcare products distributors in India (between fiscal 2019 to fiscal 2022). Entero reached ?2,500 crore operating income within 4 years of operations. Entero leverages technology to provide a positive buying experience through their digital solutions such as the Entero Direct B2B application (“Entero Direct”),

• Entero is among the Top-3 healthcare products distributor in India to have wide network reach with retail pharmacies in India. Entero catered to 39,500+, 64,200+, 81,400+, 65,000+ and 73,700+ retail pharmacies in fiscal 2021, fiscal 2022, fiscal 2023, 6 months ended September 2022 and 6 months ended September 2023, respectively.

• Entero has the largest hospital customer network among the pharmaceutical products distributors in India. Entero catered to 1600+, 2,500+, 3,400+, 2,400+ and 2,800+ hospital customers in fiscal 2021, fiscal 2022, fiscal 2023, 6 months ended September 2022 and 6 months ended September 2023, respectively.

• The market share for Entero in Indian pharmaceutical and medical devices distribution industry (total size: 2,66,904 crore) is 1.24% as of fiscal 2023.

• They have entered into an agreement with Roche Products (India) Pvt Ltd for the promotion, marketing, and distribution of its 4 nephrology drugs in India.

Strengths

Competitive Strength 

• The Company operates in the large and highly fragmented Indian healthcare products distribution market and expect to benefit from market consolidation;

• One of India’s largest and fastest growing healthcare products distribution platforms;

• Track record of inorganic expansion and integration to grow the geographic reach, revenues and scale;

• Differentiated business model offering comprehensive and integrated commercial and supply chain solutions;

• Proprietary technology platform with integrated business intelligence tools and solutions;

• Experienced, committed and qualified founding and professional management team with deep industry expertise and backed by healthcare focused investor.

Business Strategies 

• Benefit from healthcare products distribution market consolidation with strategic acquisitions;
• Strengthen market position through increases in customer base, wallet share and geographic penetration;
• Pursue comprehensive marketing and distribution collaborations with healthcare product manufacturers;
• Expand the product adjacencies, private label and service offerings;

• Continue to invest in and leverage the technology, scale and synergistic adjacencies to drive efficiencies and profitability.

Company Promoters

Company Financials

Entero Healthcare Solutions Limited's revenue increased by 30.84% and profit after tax (PAT) rose by 62.28% between the financial year ending with March 31, 2023 and March 31, 2022.

Objects of the Issue

The Company proposes to utilize the Net Proceeds from the Fresh Issue towards funding the following objects:

• Repayment/prepayment, in full or part, of certain borrowings availed of by the company and our Subsidiaries.
• Funding the long term working capital requirements.
• Pursuing inorganic growth initiatives through acquisitions.
• General corporate purposes.